Outcomes of SDHB Pathogenic Variant Carriers
The Journal of Clinical Endocrinology & Metabolism · 13.08.2024 · 109 (9) · 2400-2410
DOI: 10.1210/clinem/dgae233 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.04.2024. Verfasst von Dahlia F Davidoff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. Hauptthemen laut MEDLINE: Succinate Dehydrogenase, Paraganglioma, Adrenal Gland Neoplasms, Pheochromocytoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: RACP Foundation.
Abstract (Originalsprache)
Context
Carriers of germline pathogenic variants (PVs) in succinate dehydrogenase type B (SDHB) are at increased risk of developing pheochromocytomas and paragangliomas (PPGLs). Understanding their outcomes can guide recommendations for risk assessment and early detection.
Objective
We performed a systematic review and meta-analysis of the following outcomes in SDHB PV carriers: age-specific risk of developing tumors, metastatic progression, second primary tumor development, and mortality.
Methods
PubMed, MEDLINE, and EMBASE were searched. Sixteen studies met the inclusion criteria and were sorted into 4 outcome categories: age-specific penetrance, metastatic disease, risk of second tumor, and mortality. We assessed heterogeneity and performed a meta-analysis across studies using a random-effects model with the DerSimonian and Laird method.
Results
Penetrance of PPGLs for nonproband/nonindex SDHB PV carriers by age 20 was 4% (95% CI, 3%-6%), 11% (95% CI, 8%-15%) by age 40, 24% (95% CI, 19%-31%) by age 60%, and 35% (95% CI, 25%-47%) by age 80. The overall risk of metastatic disease for nonproband/nonindex carriers with PPGLs was 9% (95%, CI 5%-16%) per lifetime. In all affected cases (combining both proband/index and nonproband/nonindex carriers with tumors), the risk of a second tumor was 24% (95% CI, 18%-31%) and all-cause 5-year mortality was 18% (95% CI, 6%-40%).
Conclusion
Penetrance for PPGLs in SDHB PV carriers increases linearly with age. Affected carriers are at risk of developing and dying of metastatic disease, or of developing second tumors. Lifelong surveillance is appropriate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
- Faculty of Medicine and Health, University of Sydney, Northern Sydney (Arabanoo) Precinct, St Leonards, NSW 2065, Australia.
- Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, Haymarket, Sydney 2007, Australia.
ORCID-Profile: Dahlia F Davidoff, Roderick J Clifton-Bligh
Förderung
- RACP Foundation
Zitieren
APA
Davidoff, D. F., De Abreu Lourenco, R., Tsang, V. H. M., Benn, D. E., & Clifton-Bligh, R. J. (2024). Outcomes of SDHB Pathogenic Variant Carriers. The Journal of Clinical Endocrinology & Metabolism, 109(9), 2400-2410. https://doi.org/10.1210/clinem/dgae233
Vancouver
Davidoff DF, De Abreu Lourenco R, Tsang VHM, Benn DE, Clifton-Bligh RJ. Outcomes of SDHB Pathogenic Variant Carriers. The Journal of Clinical Endocrinology & Metabolism. 2024;109(9):2400-2410. doi:10.1210/clinem/dgae233
BibTeX
@article{Davidoff2024,
author = {Davidoff, Dahlia F and De Abreu Lourenco, Richard and Tsang, Venessa H M and Benn, Diana E and Clifton-Bligh, Roderick J},
title = {Outcomes of SDHB Pathogenic Variant Carriers},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {9},
pages = {2400--2410},
doi = {10.1210/clinem/dgae233}
}
EUVIMED